Desferri-ferrithiocin

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Desferri-ferrithiocin
• 英文别名: 2-(3-hydroxypyridin-2-yl)-4-methyl-5H-1,3-thiazole-4-carboxylic acid
• 化学式: C₁₀H₁₀N₂O₃S
• 分子量: 238.267
• InChiKey: MJWAGSZZOQMRNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  重氮甲烷 、 Desferri-ferrithiocin 以 甲醇 、 乙醚 、 水 为溶剂， 以58%的产率得到Desferri-O-methyl-ferrithiocinmethylester
  参考文献：
  名称：

  Stoffwechselprodukte von Mikroorganismen。193.Mitteilung。铁硫霉素†

  摘要：

  微生物的代谢产物。铁硫霉素

  DOI：

  10.1002/hlca.19800630608

文献信息

• TARGETED IONOPHORE-BASED METAL DELIVERY
  申请人：The Regents of the University of California

  公开号：US20200113937A1

  公开（公告）日：2020-04-16

  The present disclosure provides ionophore compounds, which are useful for facilitating delivery of a metal ion to a cell, tissue or organ of interest. The present disclosure provides compositions comprising the subject ionophore compounds. The present disclosure provides methods of delivering a metal ion intracellularly to a target cell. The present disclosure also provides methods of treating a condition associated with a metal deficiency in an individual.

  本公开提供离子载体化合物，用于促进金属离子传递至感兴趣的细胞、组织或器官。本公开提供包含所述离子载体化合物的组合物。本公开提供将金属离子胞内传递至靶细胞的方法。本公开还提供治疗个体金属缺乏相关病症的方法。
• [EN] DESFERRITHIOCIN ANALOGS AND USES THEREOF<br/>[FR] ANALOGUES DE LA DESFERRITHIOCINE ET LEURS UTILISATIONS
  申请人：UNIV FLORIDA

  公开号：WO2015077655A1

  公开（公告）日：2015-05-28

  Iron overload is associated with pathological conditions such as oxidative stress, transfusional iron overload, thalassemia, primary hemochromatosis, secondary hemochromatosis, diabetes, liver disease, heart disease, cancer, radiation injury, neurological or neurodegenerative disorder, Friedreich's ataxia (FRDA), macular degeneration, closed head injury, irritable bowel disease, and reperfusion injury. The present invention provides methods and pharmaceutical compositions using desferrithiocin analogs of Formulae (A) and (J) for treating and/or preventing these pathological conditions, metal (e.g., iron, aluminum, a lanthanide, or an actinide (e.g., uranium)) overload conditions, and infectious diseases (e.g., malaria).

  铁过载与病理条件相关，如氧化应激、输血性铁过载、地中海贫血、原发性血色病、继发性血色病、糖尿病、肝病、心脏病、癌症、放射损伤、神经或神经退行性疾病、弗里德雷希共济失调（FRDA）、黄斑变性、闭合性头部损伤、肠易激综合征和再灌注损伤。本发明提供使用式（A）和（J）的去铁胱醇类似物的方法和药物组合物，用于治疗和/或预防这些病理条件、金属（如铁、铝、镧系元素或锕系元素（如铀））过载症状和传染病（如疟疾）。
• [EN] HBED PRODRUGS AND USE THEREOF<br/>[FR] PROMÉDICAMENTS DE HEBD ET LEUR UTILISATION
  申请人：UNIV OF FLORIDA RES FOUND INCORPPORATED

  公开号：WO2017040653A1

  公开（公告）日：2017-03-09

  The present invention provides N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED) prodrugs of Formula (I), (II), and (III), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, and polymorphs for treatment or prevention of diseases that are associated with oxidative stress and/or excess metal (e.g. iron). The present invention further provides HBED prodrugs of Formula (I), (II), and (III), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, and polymorphs for the treatment and/or prevenation of macular degeneration. The provided HBED prodrugs may have improved oral availability and/or brain penentration compared to HBED.

  本发明提供了式(I)、(II)和(III)的N,N'-双(2-羟基苯甲基)乙二胺-N,N'-二乙酸（HBED）前药，以及与氧化应激和/或过量金属（例如铁）相关的疾病的治疗或预防的药用盐、互变异构体、立体异构体、溶剂合物、水合物和多晶形式。本发明还提供了式(I)、(II)和(III)的HBED前药，以及用于治疗和/或预防黄斑变性的药用盐、互变异构体、立体异构体、溶剂合物、水合物和多晶形式。所提供的HBED前药可能比HBED具有改善的口服可用性和/或脑透过性。
• [EN] METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF<br/>[FR] AGENTS CHÉLATEURS MÉTALLIQUES PROGRAMMÉS MÉTABOLIQUEMENT ET LEURS UTILISATIONS
  申请人：UNIV FLORIDA

  公开号：WO2016176343A1

  公开（公告）日：2016-11-03

  The present invention provides compounds of Formula (I), which are "metabolically programmed" metal chelators, e.g., lipophilic, absorbable (e.g., orally absorbable), and effective metal chelators that are converted in vivo to their hydrophilic, nontoxic metabolites. The present invention also provides compounds of Formula (II), which are also "metabolically programmed" metal chelators. The invention also provides pharmaceutical compositions, kits, methods, and uses that include a compound described herein. The compounds, pharmaceutical compositions, kits, and methods may be useful in treating or preventing a disease (e.g., metal overload, oxidative stress, diabetes, liver disease, heart disease, cancer, radiation injury, neurological or neurodegenerative disorder, Friedreich's ataxia (FRDA), macular degeneration, closed head injury, irritable bowel disease, reperfusion injury, metal poisoning, or infectious disease).

  本发明提供了式（I）的化合物，这些化合物是“代谢程序化”的金属螯合剂，例如，亲脂性、可吸收（例如，口服可吸收）和有效的金属螯合剂，在体内转化为其亲水性、无毒的代谢物。本发明还提供了式（II）的化合物，这些化合物也是“代谢程序化”的金属螯合剂。本发明还提供了包括本文所述化合物的药物组合物、试剂盒、方法和用途。这些化合物、药物组合物、试剂盒和方法可能对治疗或预防疾病（例如，金属过载、氧化应激、糖尿病、肝病、心脏病、癌症、放射损伤、神经系统或神经退行性疾病、弗里德雷希氏共济失调症（FRDA）、黄斑变性、闭合性头部损伤、肠易激综合征、再灌注损伤、金属中毒或传染性疾病）具有用处。
• Synthesis of benzonitriles from substituted benzaldehyde
  申请人：Genzyme Corporation

  公开号：US20030220504A1

  公开（公告）日：2003-11-27

  There is a significant demand for organic nitriles, based on their versatility in reactions. Compounds prepared from nitriles have properties including superoxide inhibition, ferrielectric liquid crystal dopant, antipicornaviral agents, anti-inflammatory agents, anti-asthma agents, and fibringoen antagonists. The present invention discloses a facile synthesis for 2,4-dihydroxybenzonitrile, and ethers and diethers thereof, from 2,4-dihydroxybenzaldehyde or 2,4-dimethoxybenzaldehyde. The present invention also discloses a method of preparing a class of iron chelating agents related to desferrithiocin, all of which contain a thiazoline ring. In this method, 2,4-dihydroxybenzonitrile is condensed with (S)-2-methylcysteine.

  有机腈的需求很大，因为它们在反应中的多功能性。从腈制备的化合物具有包括超氧化物抑制、铁电液晶掺杂剂、抗肠病毒药物、抗炎药物、抗哮喘药物和纤维蛋白原拮抗剂在内的性质。本发明揭示了一种简便的合成2,4-二羟基苯甲腈及其醚和二醚，从2,4-二羟基苯甲醛或2,4-二甲氧基苯甲醛制备。本发明还揭示了一种制备与脱铁硫胂素相关的一类铁螯合剂的方法，所有这些剂都含有噻唑环。在这种方法中，2,4-二羟基苯甲腈与(S)-2-甲基半胱氨酸缩合。